参桂胶囊辅助治疗重度充血性心力衰竭的临床疗效观察

Clinical Study of Shengui Capsule as an Adjunctive Therapy for Severe Congestive Heart Failure

目的:观察参桂胶囊辅助治疗重度充血性心力衰竭的临床疗效及安全性。方法:将重度充血性心力衰竭患者68例随机分为2组:对照组34例行常规治疗(休息、吸氧、强心、利尿、扩血管及对症等);观察组34例在常规治疗的基础上加用参桂胶囊,每次0.9g,每日3次。2组均4周为1疗程。监测2组患者用药前、后心率、血压、心电图、心脏彩超、血浆心钠素(ANF)、电解质、肌酐的变化情况。结果:参桂胶囊能较好改善心脏功能且降低血浆ANF水平,与对照组比较具有显著性差异(P<0.01)。结论:参桂胶囊辅助治疗重度充血性心力衰竭疗效较好,无明显毒副作用,可作为该症的常规治疗药物。

OBJECTIVE： To observe the clinical efficacy and safety of Shengui capsule in treating severe congestive heart failure（CHF）. METHODS： 68 patients with severe CHF were randomly divided into 2 groups： 34 patients（control group） were treated with routine therapy（rest, oxygen inhalation, inotropic agents and diuretic agents, vasodilators and symptomatic treatment） for 4 weeks, and another 34 patients with routine therapy plus 0.9 g Shengui capsule rid for 4 weeks（trial group）. HR, BP, ECG, CD（Color Doppler）, ANF（atrial natriuretic peptide）, electrolytes and SCr before and after treatment were compared between the two groups.RESULTS： The cardiac function was improved and ANF level was down - regulated in patients treated with Shengui capsule, showing significant difference as compared with control group（P 〈 0.01）. CONCLUSION： Shengui capsule showed satisfactory efficacy but less side effect as an adjunctive therapy in patients with severe CHF, and it thus can be used as routine drug for severe CHF.